From Zacks Investment Research: 2024-09-18 16:02:47

Merck announced positive results from a phase study of its patritumab deruxtecan for EGFR-mutated non-small cell lung cancer, meeting its primary endpoint of progression-free survival. The study demonstrated a statistically significant improvement in PFS compared to chemotherapy. Overall survival data is pending. Merck plans to discuss the data with regulatory authorities. The company also has a BLA under review in the US for accelerated approval. Merck acquired rights to patritumab deruxtecan from Daiichi Sankyo last year. ADCs like patritumab deruxtecan are important for treating second-line lung cancer. Pfizer and Daiichi Sankyo are also developing ADCs. Eli Lilly is a top-ranked large drugmaker with strong earnings estimates and stock performance.



Read more at Zacks Investment Research: Study: Merck and Daiichi’s Lung Cancer Treatment Shows Promise – September 18, 2024